![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: AKT2 |
Gene summary for AKT2 |
![]() |
Gene information | Species | Human | Gene symbol | AKT2 | Gene ID | 208 |
Gene name | AKT serine/threonine kinase 2 | |
Gene Alias | HIHGHH | |
Cytomap | 19q13.2 | |
Gene Type | protein-coding | GO ID | GO:0000271 | UniProtAcc | B4DG79 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
208 | AKT2 | HTA11_347_2000001011 | Human | Colorectum | AD | 1.63e-04 | 2.42e-01 | -0.1954 |
208 | AKT2 | HTA11_1391_2000001011 | Human | Colorectum | AD | 2.41e-07 | 5.08e-01 | -0.059 |
208 | AKT2 | HTA11_7663_2000001011 | Human | Colorectum | SER | 4.53e-03 | 3.82e-01 | 0.0131 |
208 | AKT2 | HTA11_7696_3000711011 | Human | Colorectum | AD | 5.11e-13 | 6.14e-01 | 0.0674 |
208 | AKT2 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 1.28e-03 | 4.11e-01 | 0.281 |
208 | AKT2 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 3.62e-17 | 7.04e-01 | 0.3859 |
208 | AKT2 | A015-C-203 | Human | Colorectum | FAP | 3.18e-02 | -9.16e-02 | -0.1294 |
208 | AKT2 | A015-C-104 | Human | Colorectum | FAP | 3.58e-02 | -1.94e-02 | -0.1899 |
208 | AKT2 | A002-C-016 | Human | Colorectum | FAP | 4.42e-02 | -1.01e-01 | 0.0521 |
208 | AKT2 | A002-C-116 | Human | Colorectum | FAP | 6.07e-04 | -1.15e-01 | -0.0452 |
208 | AKT2 | LZE4T | Human | Esophagus | ESCC | 2.91e-02 | 6.89e-03 | 0.0811 |
208 | AKT2 | LZE5T | Human | Esophagus | ESCC | 3.80e-02 | 1.06e-01 | 0.0514 |
208 | AKT2 | LZE7T | Human | Esophagus | ESCC | 1.46e-04 | 2.22e-01 | 0.0667 |
208 | AKT2 | LZE8T | Human | Esophagus | ESCC | 7.65e-04 | 1.62e-01 | 0.067 |
208 | AKT2 | LZE22T | Human | Esophagus | ESCC | 3.32e-03 | 1.35e-01 | 0.068 |
208 | AKT2 | LZE24T | Human | Esophagus | ESCC | 8.07e-16 | 3.56e-01 | 0.0596 |
208 | AKT2 | LZE21T | Human | Esophagus | ESCC | 3.26e-08 | 2.21e-01 | 0.0655 |
208 | AKT2 | P1T-E | Human | Esophagus | ESCC | 1.55e-06 | 4.97e-01 | 0.0875 |
208 | AKT2 | P2T-E | Human | Esophagus | ESCC | 5.00e-29 | 4.34e-01 | 0.1177 |
208 | AKT2 | P4T-E | Human | Esophagus | ESCC | 1.08e-11 | 2.47e-01 | 0.1323 |
Page: 1 2 3 4 5 6 7 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0006091 | Colorectum | AD | generation of precursor metabolites and energy | 209/3918 | 490/18723 | 3.17e-28 | 6.61e-25 | 209 |
GO:0015980 | Colorectum | AD | energy derivation by oxidation of organic compounds | 143/3918 | 318/18723 | 2.78e-22 | 2.49e-19 | 143 |
GO:0072659 | Colorectum | AD | protein localization to plasma membrane | 122/3918 | 284/18723 | 2.86e-17 | 1.49e-14 | 122 |
GO:0009896 | Colorectum | AD | positive regulation of catabolic process | 180/3918 | 492/18723 | 4.33e-16 | 1.94e-13 | 180 |
GO:0031331 | Colorectum | AD | positive regulation of cellular catabolic process | 156/3918 | 427/18723 | 4.68e-14 | 1.05e-11 | 156 |
GO:1990778 | Colorectum | AD | protein localization to cell periphery | 129/3918 | 333/18723 | 5.51e-14 | 1.15e-11 | 129 |
GO:1903829 | Colorectum | AD | positive regulation of cellular protein localization | 110/3918 | 276/18723 | 4.58e-13 | 8.44e-11 | 110 |
GO:0090150 | Colorectum | AD | establishment of protein localization to membrane | 100/3918 | 260/18723 | 6.01e-11 | 6.33e-09 | 100 |
GO:0048732 | Colorectum | AD | gland development | 149/3918 | 436/18723 | 6.07e-11 | 6.33e-09 | 149 |
GO:1905475 | Colorectum | AD | regulation of protein localization to membrane | 73/3918 | 175/18723 | 3.37e-10 | 2.93e-08 | 73 |
GO:1904951 | Colorectum | AD | positive regulation of establishment of protein localization | 112/3918 | 319/18723 | 2.55e-09 | 1.80e-07 | 112 |
GO:0051222 | Colorectum | AD | positive regulation of protein transport | 106/3918 | 303/18723 | 8.45e-09 | 5.08e-07 | 106 |
GO:0006605 | Colorectum | AD | protein targeting | 105/3918 | 314/18723 | 1.39e-07 | 6.44e-06 | 105 |
GO:1905477 | Colorectum | AD | positive regulation of protein localization to membrane | 46/3918 | 106/18723 | 1.47e-07 | 6.64e-06 | 46 |
GO:0016050 | Colorectum | AD | vesicle organization | 101/3918 | 300/18723 | 1.65e-07 | 7.17e-06 | 101 |
GO:0090316 | Colorectum | AD | positive regulation of intracellular protein transport | 62/3918 | 160/18723 | 1.82e-07 | 7.79e-06 | 62 |
GO:0032388 | Colorectum | AD | positive regulation of intracellular transport | 74/3918 | 202/18723 | 1.83e-07 | 7.80e-06 | 74 |
GO:0032868 | Colorectum | AD | response to insulin | 91/3918 | 264/18723 | 2.02e-07 | 8.48e-06 | 91 |
GO:0032386 | Colorectum | AD | regulation of intracellular transport | 109/3918 | 337/18723 | 5.33e-07 | 1.95e-05 | 109 |
GO:0033157 | Colorectum | AD | regulation of intracellular protein transport | 80/3918 | 229/18723 | 5.81e-07 | 2.09e-05 | 80 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0515211 | Oral cavity | OSCC | Tuberculosis | 105/3704 | 180/8465 | 5.00e-05 | 2.04e-04 | 1.04e-04 | 105 |
hsa05017111 | Oral cavity | OSCC | Spinocerebellar ataxia | 86/3704 | 143/8465 | 5.21e-05 | 2.08e-04 | 1.06e-04 | 86 |
hsa04066112 | Oral cavity | OSCC | HIF-1 signaling pathway | 68/3704 | 109/8465 | 6.30e-05 | 2.48e-04 | 1.26e-04 | 68 |
hsa0401015 | Oral cavity | OSCC | MAPK signaling pathway | 165/3704 | 302/8465 | 7.11e-05 | 2.74e-04 | 1.40e-04 | 165 |
hsa04810111 | Oral cavity | OSCC | Regulation of actin cytoskeleton | 129/3704 | 229/8465 | 7.14e-05 | 2.74e-04 | 1.40e-04 | 129 |
hsa0401217 | Oral cavity | OSCC | ErbB signaling pathway | 55/3704 | 85/8465 | 7.46e-05 | 2.81e-04 | 1.43e-04 | 55 |
hsa0514212 | Oral cavity | OSCC | Chagas disease | 64/3704 | 102/8465 | 8.00e-05 | 2.95e-04 | 1.50e-04 | 64 |
hsa0521319 | Oral cavity | OSCC | Endometrial cancer | 40/3704 | 58/8465 | 8.86e-05 | 3.19e-04 | 1.62e-04 | 40 |
hsa0521416 | Oral cavity | OSCC | Glioma | 49/3704 | 75/8465 | 1.27e-04 | 4.50e-04 | 2.29e-04 | 49 |
hsa0522517 | Oral cavity | OSCC | Hepatocellular carcinoma | 97/3704 | 168/8465 | 1.63e-04 | 5.52e-04 | 2.81e-04 | 97 |
hsa04919112 | Oral cavity | OSCC | Thyroid hormone signaling pathway | 73/3704 | 121/8465 | 1.63e-04 | 5.52e-04 | 2.81e-04 | 73 |
hsa052351 | Oral cavity | OSCC | PD-L1 expression and PD-1 checkpoint pathway in cancer | 56/3704 | 89/8465 | 1.97e-04 | 6.55e-04 | 3.33e-04 | 56 |
hsa0466619 | Oral cavity | OSCC | Fc gamma R-mediated phagocytosis | 60/3704 | 97/8465 | 2.35e-04 | 7.72e-04 | 3.93e-04 | 60 |
hsa0415012 | Oral cavity | OSCC | mTOR signaling pathway | 90/3704 | 156/8465 | 2.87e-04 | 9.15e-04 | 4.66e-04 | 90 |
hsa0522315 | Oral cavity | OSCC | Non-small cell lung cancer | 46/3704 | 72/8465 | 4.37e-04 | 1.32e-03 | 6.72e-04 | 46 |
hsa0415113 | Oral cavity | OSCC | PI3K-Akt signaling pathway | 185/3704 | 354/8465 | 6.26e-04 | 1.86e-03 | 9.49e-04 | 185 |
hsa0415212 | Oral cavity | OSCC | AMPK signaling pathway | 71/3704 | 121/8465 | 6.29e-04 | 1.86e-03 | 9.49e-04 | 71 |
hsa0421113 | Oral cavity | OSCC | Longevity regulating pathway | 54/3704 | 89/8465 | 9.24e-04 | 2.65e-03 | 1.35e-03 | 54 |
hsa0492615 | Oral cavity | OSCC | Relaxin signaling pathway | 74/3704 | 129/8465 | 1.20e-03 | 3.37e-03 | 1.72e-03 | 74 |
hsa0522112 | Oral cavity | OSCC | Acute myeloid leukemia | 42/3704 | 67/8465 | 1.34e-03 | 3.75e-03 | 1.91e-03 | 42 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
AKT2 | SNV | Missense_Mutation | c.867N>G | p.Ile289Met | p.I289M | P31751 | protein_coding | deleterious(0) | possibly_damaging(0.896) | TCGA-A1-A0SI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
AKT2 | SNV | Missense_Mutation | c.1066N>A | p.Glu356Lys | p.E356K | P31751 | protein_coding | deleterious(0.02) | probably_damaging(0.934) | TCGA-C8-A1HM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | CR | |
AKT2 | SNV | Missense_Mutation | novel | c.976N>A | p.Asp326Asn | p.D326N | P31751 | protein_coding | deleterious(0.04) | possibly_damaging(0.831) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
AKT2 | SNV | Missense_Mutation | novel | c.133N>G | p.Pro45Ala | p.P45A | P31751 | protein_coding | tolerated(0.77) | benign(0) | TCGA-EX-A3L1-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
AKT2 | SNV | Missense_Mutation | novel | c.90G>C | p.Lys30Asn | p.K30N | P31751 | protein_coding | tolerated(0.22) | benign(0.111) | TCGA-JW-A5VJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
AKT2 | SNV | Missense_Mutation | c.1278N>G | p.Phe426Leu | p.F426L | P31751 | protein_coding | deleterious(0.01) | probably_damaging(0.94) | TCGA-LP-A4AV-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
AKT2 | SNV | Missense_Mutation | novel | c.401N>G | p.Glu134Gly | p.E134G | P31751 | protein_coding | tolerated(0.08) | benign(0.003) | TCGA-A6-6780-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
AKT2 | SNV | Missense_Mutation | novel | c.1021T>C | p.Tyr341His | p.Y341H | P31751 | protein_coding | deleterious(0.03) | probably_damaging(0.976) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
AKT2 | SNV | Missense_Mutation | c.1189N>T | p.Pro397Ser | p.P397S | P31751 | protein_coding | tolerated(0.16) | benign(0.035) | TCGA-AA-A01R-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5-fluorouracil | PD | |
AKT2 | SNV | Missense_Mutation | rs757245351 | c.803C>T | p.Ser268Leu | p.S268L | P31751 | protein_coding | tolerated(0.07) | benign(0.082) | TCGA-AZ-4615-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | xeloda | PD |
Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
208 | AKT2 | CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR | inhibitor | CHEMBL2177390 | IPATASERTIB | |
208 | AKT2 | CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR | GDC-0068 | IPATASERTIB | ||
208 | AKT2 | CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR | allosteric modulator | 405560349 | ||
208 | AKT2 | CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR | TRICIRIBINE | TRICIRIBINE | ||
208 | AKT2 | CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR | inhibitor | 223366042 | CAPIVASERTIB | |
208 | AKT2 | CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR | inhibitor | CHEMBL3545134 | LY-2780301 | |
208 | AKT2 | CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR | inhibitor | 249565578 | IPATASERTIB | |
208 | AKT2 | CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR | AFURESERTIB HYDROCHLORIDE | |||
208 | AKT2 | CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR | allosteric modulator | 249565628 | MK-2206 | |
208 | AKT2 | CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR | inhibitor | MK2206 | MK-2206 |
Page: 1 2 3 4 5 |